Drug intelligence / Profile preview

Calcisol-CCZ

Development stage: Unknown
Lead developer: Boffin Biotech
Modality: Small Molecules
Administration: Oral

Overview

Calcisol-CCZ is an oral combination supplement developed by Boffin Biotech, containing calcitriol, calcium carbonate, and zinc. It is primarily indicated for the prevention and treatment of calcium and vitamin D deficiencies, as well as bone-related disorders such as osteoporosis, osteomalacia, rickets, and hypocalcemia. Calcitriol, the active metabolite of vitamin D3, binds to the vitamin D receptor (VDR) to enhance intestinal absorption of calcium and phosphate. Calcium carbonate serves as an elemental calcium source to support bone mineralization and density, while zinc acts as an essential cofactor that stimulates bone-building osteoblasts and inhibits bone-resorbing osteoclasts.

Brand names: Calcisol-CCZ
Other names: Calcitriol + Calcium Carbonate + ZincCalcitriol, Calcium & Zinc Capsules

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Calcisol-CCZ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcisol-CCZ.